Methotrexate Orion Pharma (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate, a molecule needed for synthesising purine nucleotides and thymidylate. This interruption reduces DNA, RNA and protein synthesis, limiting the proliferation of rapidly dividing cells such as activated T‑lymphocytes and malignant cells. Additionally, methotrexate increases extracellular adenosine, which contributes to its anti‑inflammatory properties.

The dose of methotrexate is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Dosing regimens can vary widely, ranging from low weekly doses for autoimmune conditions to higher doses given in cycles for oncology protocols. Patients should follow the exact dosing instructions provided by their healthcare professional.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women because it can cause fetal malformations and miscarriage. Women of child‑bearing potential must use effective contraception during treatment and for several months after discontinuation. The drug is also excreted in breast milk and is not recommended while breastfeeding.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

The primary alternatives for autoimmune conditions are biologic disease‑modifying antirheumatic drugs (bDMARDs) such as TNF‑α inhibitors. Compared with biologics, methotrexate is an oral, lower‑cost option with a well‑established safety profile, but it may be less rapid in controlling severe disease. For oncology, methotrexate is one of several antimetabolites; its efficacy and toxicity differ from agents like 5‑fluorouracil or cytarabine, influencing regimen selection.

Methotrexate Orion Pharma should be stored at temperatures below 25 °C (77 °F) in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight. No special refrigeration is required for the oral formulation.

The medication is administered orally, typically as a tablet that should be swallowed whole with a full glass of water. It is usually taken once weekly, on the same day each week, and may be taken with or without food according to the prescriber’s advice. Folate supplementation is often recommended to reduce certain side effects, but patients should follow their clinician’s guidance.

Patients should be alert for signs of severe liver toxicity (jaundice, dark urine), pulmonary complications (new shortness of breath, dry cough), bone‑marrow suppression (persistent fever, unusual bruising or bleeding), and renal impairment (decreased urine output, swelling). Prompt medical evaluation is essential if any of these symptoms develop, as early detection can prevent serious outcomes.

Methotrexate is contraindicated in pregnant women, individuals with known hypersensitivity to the drug, patients with severe hepatic disease (e.g., cirrhosis), significant renal impairment (creatinine clearance <30 mL/min), and those with active, uncontrolled infections. Caution is also advised for patients with pre‑existing blood dyscrasias or pulmonary disease.